IFM Therapeutics launched a second subsidiary in less than a year. The Boston-based company launched IFM Due, a subsidiary company developing a suite of cGAS inhibitors and STING antagonists that can target diseases such as NASH, lupus and Parkinson’s.

Sanofi reportedly ended 38 R&D programs and is prioritizing oncology, immunology, rare disease and rare blood disorders.

Many of the largest U.S. pharmacies and drug distributors do not have Teva Pharmaceutical Industries Ltd.’s generic version of EpiPen five months after the life-saving allergy treatment was approved for sale in the United States, pharmacy chains and a group that tracks drug shortages told Reuters.

Indivior said a U.S. district court had granted the British drugmaker a temporary restraining order, stopping rival Alvogen from launching cut-price versions of the company’s blockbuster opioid addiction treatment.

Teva Pharmaceutical Industries Ltd. said the drugmaker will pay an undisclosed amount to settle an ongoing dispute with Amgen Inc. over the company’s generic cinacalcet hydrochloride (HCl) product.

Shares of Eli Lilly were up nearly 5 percent in premarket trading after the company announced financial guidance for 2019 showing expected revenue of between $25.3 billion and $25.8 billion that will be driven by revenue from branded drugs such as Trulicity, Taltz, Verzenio and the newly launched Emgality.

In the initial excitement over the possibilities of mobile marketing, pharma rushed to create its own apps. And then these apps languished.

Durham, North Carolina-based Ribometrix closed on a Series A financing worth $30 million, led by M Ventures.

Swiss pharma giant Novartis announced plans to seek regulatory approval for 60 new treatments between 2019 and 2021.

Indian drugmaker Dr. Reddy’s Laboratories posted a 69.7 percent jump in fiscal second-quarter 2018 profit, helped by new product launches.